Celldex Therapeutics Inc. (CLDX)
Celldex Announces Initial Positive Results from Phase 1 Trial of CDX-622 Demonstrating Favorable Safety and PK Profile and Sustained Mast Cell Inhibition
Celldex Announces Initial Positive Results from Phase 1 Trial of CDX-622 Demonstrating Favorable Safety and PK Profile and Sustained Mast Cell Inhibition
📈 **POSITIVE** • Medium confidence analysis (68%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business